Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06771323 · ClinicalTrials.gov registry record · Phase 2

Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia

A Phase 2 study of Cervical Dystonia, sponsored by Virginia Commonwealth University.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT06771323 is a Phase 2 study of Cervical Dystonia that is actively recruiting participants, run by Virginia Commonwealth University. The registered enrollment target is 20 participants, below the 86-participant average among 15 other Cervical Dystonia trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06771323, a Phase 2 study of Cervical Dystonia, is actively recruiting participants, sponsored by Virginia Commonwealth University.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The most common form of idiopathic dystonia is adult-onset cervical dystonia (CD), a focal form of dystonia affecting the muscles of the neck. CD is often associated with pain and limited range of motion, and frequently leads to reduced quality of life and disability. Effective long-term treatment options are extremely limited. Recurring botulinum neurotoxin (BoNT) injections can ease the symptoms of CD, but they frequently provide only partial relief and can be associated with intolerable side effects. Deep brain stimulation can be used to treat more severe cases of CD, but this neurosurgical procedure is invasive, on average only about 50% effective and may lead to serious adverse effects. Novel treatment approaches for CD are desperately needed to alleviate symptoms and improve the quality of life for the many who suffer from this chronic and disabling neurological disorder.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Valbenazine

Study Locations (1)

Virginia

  • Virginia Commonwealth University - Richmond

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-12-17
Est. Completion 2026-01
Phase Phase 2

Sponsor

Virginia Commonwealth University

558 total trials

What the Registry Record Tells You About NCT06771323

The ClinicalTrials.gov registry entry for NCT06771323 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 15 other Cervical Dystonia trials with a reported enrollment target (77% lower). The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Dystonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06771323 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT06771323 about?

NCT06771323 is a clinical study titled "Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia". The most common form of idiopathic dystonia is adult-onset cervical dystonia (CD), a focal form of dystonia affecting the muscles of the neck. CD is often associated with pain and limited range of motion, and frequently leads to reduced quality of life and disability. Effective long-term treatment o...

What is the current status of trial NCT06771323?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-12-17. Estimated completion is 2026-01.

What conditions does trial NCT06771323 study?

This clinical trial studies the following conditions: Cervical Dystonia.

What interventions are being tested in trial NCT06771323?

The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).

Who is sponsoring clinical trial NCT06771323?

This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06771323 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cervical Dystonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.